Peptide Cycling Protocols: BPC-157, TB-500, and GHK-Cu Dosing Explained

What Is Peptide Cycling and Why Does It Matter?

Peptide cycling is the practice of administering a peptide compound for a defined on-period, then stopping entirely for an off-period before repeating. The goal is to prevent receptor downregulation and maintain physiological sensitivity to the peptide's signaling effects. A typical structure is 8 weeks on and 4 weeks off, though the correct ratio depends on the compound, the dose, and the clinical indication.

Peptides are short chains of amino acids, usually 2 to 50 residues, that act as signaling molecules at the cellular level. Unlike small-molecule drugs, most therapeutic peptides are degraded rapidly by circulating peptidases, giving them short half-lives that range from minutes to a few hours [1]. That pharmacokinetic reality shapes every cycling decision: dosing frequency, injection timing, and the length of the rest phase all follow from how quickly a given peptide clears and how persistently it alters receptor expression.

The distinction between micrograms and milligrams matters enormously in this space. A dosing error of 10-fold is clinically significant. BPC-157, for example, is active in animal models at doses as low as 10 nanograms per kilogram, which translates to human-equivalent doses well below 1 mg per day [2]. Writing a dose as "1 mg" when you mean "1 mcg" is not a formatting preference. It is a safety-critical distinction that every patient and prescriber must internalize before a single vial is reconstituted.

BPC-157 Dosing: mcg vs mg, Schedule, and Cycle Length

BPC-157 (Body Protection Compound 157) is a 15-amino-acid partial sequence of human gastric juice protein BPC. Published rodent data show reproducible pro-healing effects on tendon, gut mucosa, bone, and peripheral nerve tissue. The compound has not completed Phase III trials in humans, and the FDA has not approved it as a drug [3].

Standard dose range. Most compounding-pharmacy protocols and the preclinical literature converge on 200 to 500 mcg per day for subcutaneous injection [2]. Oral capsule formulations are also used for gut-specific indications at the same mcg range, though bioavailability data in humans are limited.

mcg vs mg. 500 mcg equals 0.5 mg. 250 mcg equals 0.25 mg. Many patients reconstitute a 5 mg vial in 2.5 mL bacteriostatic water, yielding a concentration of 2 to 000 mcg/mL (or 2 mcg/µL). A 250 mcg dose at that concentration is 0.125 mL, drawn to the 12.5-unit mark on a U-100 insulin syringe. Writing the dose in mcg at every step prevents the most common dosing error.

Injection site. For systemic effects, injecting near the injury site (perilesional) may produce faster local benefit. A rodent Achilles tendon study using perilesional BPC-157 at 10 mcg/kg showed measurable tendon load-to-failure improvement at 14 days versus saline controls [2]. For gut mucosal indications, oral administration is used.

Cycle structure for BPC-157.

• Loading: 250 to 500 mcg once daily for the first 2 weeks.
• Continuation: 200 to 250 mcg once daily, weeks 3 to 8.
• Off period: 4 weeks minimum before repeating.
• Acute injury protocol: Some clinicians run a shorter, higher-dose phase of 500 mcg twice daily for 10 to 14 days, then taper.

BPC-157 appears to upregulate growth hormone receptor expression and stimulate vascular endothelial growth factor (VEGF) in the peri-injury zone [4]. Because VEGF signaling can theoretically promote angiogenesis in ways that are context-dependent, patients with a personal or family history of solid-tumor malignancy should discuss this mechanism with their oncologist before starting.

TB-500 Dosing: Loading, Maintenance, and Cycle Architecture

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), specifically the actin-binding domain sequence Ac-SDKPDMAEIEKFDKSKLKTET. Thymosin beta-4 is a 43-amino-acid protein produced endogenously in most human cell types [5]. It binds G-actin to promote cellular migration, angiogenesis, and tissue remodeling after injury. TB-500 retains the core bioactivity of the full protein in a smaller, more stable molecule.

Loading phase. The rationale for a loading phase mirrors that of other tissue-remodeling agents: saturating tissue compartments before dropping to a maintenance dose.

• Weeks 1 to 6: 4 to 8 mg per week, divided into two subcutaneous injections (e.g., 2 to 4 mg on Monday and Thursday).
• Higher end of this range (6 to 8 mg/week) is typically reserved for acute musculoskeletal injury or post-surgical recovery.

Maintenance phase.

• After the loading phase: 2 to 2.5 mg every 2 weeks.
• This phase runs until the clinical endpoint is reached, usually 4 to 8 additional weeks.

Off period. Most clinical protocols recommend a minimum 4-week washout after a full 10 to 12-week course before reassessing need. Because TB-500 modulates cytoskeletal dynamics and macrophage recruitment, running consecutive cycles without a break has no published safety data in humans [6].

Reconstitution. A typical 10 mg vial reconstituted in 2 mL bacteriostatic water yields 5 mg/mL. A 2 mg dose draws to 0.4 mL on a standard 1 mL syringe. Refrigerate at 2 to 8°C after reconstitution. Discard unused solution after 28 days.

A 2023 review in the International Journal of Molecular Sciences summarized the mechanistic evidence for thymosin beta-4 in wound healing, noting that Tβ4 "promotes angiogenesis, reduces inflammation, and supports keratinocyte migration in a coordinated repair sequence" [6]. TB-500's fragment retains the actin-sequestering domain responsible for most of those effects.

GHK-Cu Dosing: Topical vs Injectable Protocols

GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is a naturally occurring copper-peptide complex first isolated from human plasma albumin in 1973. Plasma concentrations of GHK-Cu are approximately 200 ng/mL in young adults but decline to roughly 80 ng/mL by age 60, a drop that correlates with slower wound healing and reduced collagen synthesis [7]. That decline is part of the biological rationale for exogenous supplementation.

Topical dosing. Topical formulations are the most widely studied and the most accessible route for GHK-Cu. Published controlled trials have used concentrations ranging from 0.1% to 5% in cream or serum vehicles.

• A 12-week double-blind study (N=67) comparing a 1% GHK-Cu cream to vehicle alone found statistically significant improvements in skin laxity (P<0.01), fine-line depth, and keratinocyte thickness on biopsy [8].
• Standard clinical protocols use a 1 to 3% concentration applied once daily at night, or a 0.5 to 1% concentration used twice daily.
• Leave-on serums typically outperform rinse-off formulations because absorption occurs over 6 to 8 hours of contact time.

Injectable dosing. Injectable GHK-Cu is used for systemic or deeper tissue effects, including hair follicle stimulation and subcutaneous tissue remodeling.

• Dose: 1 to 2 mg per injection, 2 to 3 sessions per week.
• Common sites: subcutaneous abdomen for systemic effect; intradermal scalp for hair density applications.
• Cycle: 8 to 12 weeks on, 4 weeks off.

GHK-Cu stimulates collagen and glycosaminoglycan synthesis, activates matrix metalloproteinases for tissue remodeling, and has shown anti-inflammatory activity by suppressing TNF-alpha and IL-6 expression in vitro [9]. A 2018 analysis in Biomolecules by Pickart and colleagues cataloged over 50 gene-expression changes induced by GHK-Cu, including upregulation of genes involved in DNA repair and antioxidant defense [9].

Combining Peptides: Stacking BPC-157, TB-500, and GHK-Cu

Some practitioners combine these three peptides simultaneously. The theoretical basis is complementary mechanisms: BPC-157 drives VEGF-mediated vascularization and growth hormone receptor sensitization, TB-500 mobilizes G-actin for cellular migration and anti-inflammatory signaling, and GHK-Cu remodels the extracellular matrix and supports collagen cross-linking [2, 5, 9].

No published head-to-head human trial has tested this specific combination. The evidence base for stacking remains preclinical and anecdotal.

A practical tiered approach to stacking, as used in the HealthRX clinical review process:

• Tier 1 (injury recovery): BPC-157 500 mcg daily + TB-500 4 mg twice weekly for 6 weeks, then reduce BPC-157 to 250 mcg daily and TB-500 to 2 mg biweekly for 4 more weeks. Off period: 4 weeks minimum.
• Tier 2 (skin and tissue remodeling): GHK-Cu 1 to 2 mg injectable 3 times weekly + topical 2% GHK-Cu serum nightly. Run for 8 to 12 weeks, then 4 weeks off.
• Tier 3 (combined performance and recovery): All three simultaneously, using Tier 1 dosing for BPC-157 and TB-500 plus Tier 2 injectable GHK-Cu at 1 mg three times weekly. This tier requires the most active physician monitoring, including CBC and metabolic panel at baseline, week 6, and post-cycle.

Injections of different peptides should be given at separate sites or at separate times of day to minimize local inflammatory overlap. Rotating injection sites within each session reduces subcutaneous nodule formation.

Regulatory Status, Safety Profile, and What Patients Must Understand

BPC-157 and TB-500 are not approved drugs in the United States. The FDA classifies them as research chemicals; they are not approved for human administration under an NDA or BLA [3]. Some compounding pharmacies have prepared them under 503A or 503B frameworks, but the FDA has taken enforcement action against compounding pharmacies producing "bulk" peptide drugs outside an approved pathway. Patients obtaining these compounds should confirm the pharmacy's registration status and request a certificate of analysis.

GHK-Cu has a different regulatory profile. Topical cosmetic formulations containing GHK-Cu are legally sold under FDA cosmetic regulations and do not require a prescription. Injectable GHK-Cu prepared by a licensed compounding pharmacy occupies a regulatory middle ground similar to BPC-157 and TB-500.

Adverse effects reported in the literature and case series.

• BPC-157: mild nausea, dizziness, and injection-site warmth in a minority of users. No serious adverse events have been documented in the published preclinical literature at standard doses [2].
• TB-500: fatigue and transient headache during the loading phase. Theoretical concern about promoting angiogenesis in occult malignancy, by the same mechanism that makes it attractive for tissue repair [6].
• GHK-Cu topical: contact dermatitis in patients with metal sensitization. Systemic injectable: limited safety data; no published serious adverse event reports at doses below 3 mg per session [8].

Patients on anticoagulants, those with a history of malignancy, and pregnant or breastfeeding women should not use any of these peptides outside a closely supervised clinical setting. VEGF and actin-remodeling pathways are active in fetal development, and no safety data exist for these populations.

Reconstitution, Storage, and Administration Technique

Getting the dose right starts with correct reconstitution. Errors at this step produce tenfold dosing mistakes more reliably than any other part of the protocol.

Standard reconstitution for BPC-157: Add bacteriostatic water slowly along the vial wall, never directly onto the lyophilized pellet. A 5 mg vial in 2.5 mL yields 2 to 000 mcg/mL. Store at 4°C after reconstitution. Use within 28 days. Freeze the unreconstituted lyophilized powder for storage beyond 90 days.

Standard reconstitution for TB-500: A 10 mg vial in 2 mL bacteriostatic water yields 5 mg/mL. A 2 mg dose is 0.4 mL. Same cold-chain rules apply.

Injection technique. Subcutaneous injection into the lower abdomen or outer thigh is the standard site. Use a 29 to 31-gauge, 0.5-inch needle. Pinch the skin, insert at a 45-degree angle, aspirate briefly, inject slowly over 5 to 10 seconds, and withdraw the needle without rubbing the site. Rotate sites with each injection. Infrared-light exposure of the injection site for 5 to 10 minutes post-injection is used by some practitioners to reduce nodule formation, though no controlled trial has validated this step.

Discard needles and syringes in a puncture-resistant sharps container. Never recap a used needle.

Monitoring During a Peptide Cycle

A responsible protocol includes objective monitoring, not just symptom tracking.

Baseline labs before starting any cycle. Complete blood count, comprehensive metabolic panel, lipid panel, and a baseline inflammatory marker (CRP or ESR). If the patient is male and over 40, a PSA. If the patient has any history of abnormal cell growth, discuss with an oncologist before starting VEGF-modulating peptides.

Mid-cycle check at week 4 to 6. Repeat CMP to assess liver and renal function. Some practitioners also repeat CRP to confirm the expected anti-inflammatory trajectory.

Post-cycle evaluation. Reassess clinical endpoints (pain scores, range of motion, skin texture scores, photographic documentation for GHK-Cu protocols). Document outcomes before deciding whether to repeat the cycle.

A 2021 systematic review in Frontiers in Pharmacology covering peptide-based therapeutics noted that "the absence of standardized human pharmacokinetic data for most research peptides makes individual dose titration and cycle design a clinical judgment rather than a protocol-driven decision" [10]. That framing applies directly here. Dosing tables are starting points.

Frequently Asked Questions